Columnist Robin Stemple's latest excursion was a trek across the city to discover where to buy a lift chair for his ...

Sarepta plans to ask the FDA for full approval of exon-skipping Duchenne muscular dystrophy treatments Amondys 45 and Vyondys 53.

The MDA's annual conference highlighted recent breakthroughs and the outlook for future care in the neuromuscular disease community.

Dyne Therapeutics is advancing z-rostudirsen toward approval for DMD after data showed increased dystrophin and early ...

Columnist Betty Vertin says her three sons with DMD may not have a big social life, but they have a big family that makes up ...

In 2018, when Nell Choi was 9 years old, she began experiencing symptoms that led to hospitalization and a diagnosis of ...

The evidence for Elevidys is growing, and Sarepta is working to make the DMD treatment widely available, the company's ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google The latest Phase 3 trial results continue showing that deramiocel ...